A Phase 1/2 interventional study of Minimally-invasive suprachoroidal buckle in Retinal Detachment Rhegmatogenous, sponsored by Sunnybrook Health Sciences Centre. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Sunnybrook Health Sciences Centre · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Retinal Detachment with a site in Canada — 4 open to participants now, 4 under way, none of them phase 3. Retinal Detachment · Canada.
Among the 13 studies in Retinal Detachment with a site in Canada, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 1/2, and was the 13th registered.
200 studies on the registry are indexed under Retinal Detachment; 30 are open to participants now.
Browse Retinal Detachment studies →4 of the 13 studies in Retinal Detachment with a site in Canada are open now. Recruiting first, the newest first:
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
University of Toronto · Sites in Canada
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 21 Retinal Detachment studies recruiting now, 15 (71%) set no upper age limit and 4 (19%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 4 2
First in 2008; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 13 is below the median of 50 across 133 interventional studies indexed under Retinal Detachment.
Median enrollment 80 across the 12 interventional studies, 204 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 5 most frequent:
Sunnybrook Health Sciences Centre is the lead sponsor of 585 studies on the registry; 136 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Sunnybrook Health Sciences Centre has 2 studies filed under Retinal Detachment — fewer than ten, so there is no comparison to draw.
2 of the studies in Retinal Detachment with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05863312CHU de Quebec-Universite LavalREtinal Detachment Outcomes Study | 2027-07 |
| NCT07941141Sunnybrook Health Sciences CentreVisc-Buckle Trial 1 | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Retinal Detachment with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A retinal detachment is a vision-threatening condition that most often requires surgical treatment. Retinal detachments occur because a tear or hole forms in the retina through which liquid can penetrate beneath the retina, separating it from its normal position. Though current surgical treatments for retinal detachment are effective, they all have downsides, such as the need for uncomfortable head positioning after surgery, and slow recovery of vision. In this study, the investigators will test a new treatment for retinal detachment. The investigators will use a special needle to inject a gel between the layers of the eye wall to block off the breaks in the retina and heal the detachment. This procedure combines and modifies ideas from existing surgical techniques, but will eventually be less risky and have fewer disadvantages than current treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated with an investigational surgical procedure for retinal detachment repair. The procedure is a minimally-invasive modification of an established procedure called "suprachoroidal buckling".
Procedure: Minimally-invasive suprachoroidal buckle
An investigational suprachoroidal space injector (Everads Therapy) will be used to inject a bleb of commercially-available ophthalmic viscoelastic (sodium hyaluronate 2.3%; aka Healon 5) into the suprachoroidal space to create a temporary intraocular buckling effect under the causative retinal break(s).
Also known as: Visc-Buckle
Intra-operative and post-operative adverse events (Safety)
Intra-operative and post-operative adverse events will be measured and categorized using the Terminologies for Categorized Adverse Event Reporting recommended by the International Medical Device Regulators Forum (IMDRF). The following will be considered adverse events of special interest: * Inability to achieve suprachoroidal bleb intra-operatively * Intraocular hemorrhage (sub-retinal, suprachoroidal, or intravitreal) * Loss of vision * Sub-retinal injection of viscoelastic * Iatrogenic retinal tear * Elevated intraocular pressure (\>10 mmHg higher than baseline and absolute value \>30mmHg) * Significant intraocular inflammation (\>2+ anterior chamber cell or vitreous haze, or retinitis, choroiditis or scleritis) * Endophthalmitis * Ocular pain
Time frame: 12 weeks
Single operation retinal reattachment rate (in percentage) at post-op week 4 and 12
Efficacy
Time frame: 12 weeks
Time to complete retinal reattachment in days
Efficacy
Time frame: 12 weeks
Change from baseline visual acuity at post-op weeks 4 and 12 (in letters)
Efficacy
Time frame: 12 weeks
Time until buckling effect is no longer visible (in days)
Efficacy
Time frame: 12 weeks
morphopsia score at post-op weeks 4 and 12 (in M-chart score)
Efficacy
Time frame: 12 weeks
Plan to share: Undecided
Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sunnybrook Health Sciences Centre →